| Name | Title | Contact Details |
|---|
The Best Place to be Your Best What is it that makes Baptist Health South Florida distinctive and unique among other healthcare organizations? Quite simply, it`s our commitment to putting quality first in everything we do. Everything we do at Baptist Health South Florida, we do to the best of our ability. That includes supporting our team with extensive training programs, millions of dollars in tuition assistance, comprehensive benefits and more. Baptist Health South Florida is the largest faith-based, not-for-profit health care organization in the region. Its network of services, supported by more than 23,000 employees, extends throughout Miami-Dade, Broward, Palm Beach and Monroe Counties. Our facilities include Baptist Hospital, Baptist Children`s Hospital, Bethesda Hospital East & West, Boca Raton Regional Hospital, Doctors Hospital, Fishermen`s Community Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital, West Kendall Baptist Hospital, and the Miami Cancer Institute; outpatient diagnostic and surgical facilities, such as our Baptist Medical Plazas and home health care services in the region. The Miami Cancer Institute and proton therapy center will usher in a new era of innovative, precision cancer treatment that is unmatched in South Florida today. Our not-for-profit facility is on track to bring nationally renowned oncology experts to what will become a world-class destination for patients from across the U.S., the Caribbean and Latin America. Our International Center of Miami is one of the largest hospital-based international programs in America. Thousands of people each year travel to Miami from around the world to visit our respected physicians and our medical facilities.
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.
Pacific Coast Laboratories Inc is a San Leandro, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."